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Abstract
The 1994 genocide against the Tutsi destroyed the health system in Rwanda. It is impressive that a small country
like Rwanda has advanced its health system to the point of now offering near universal health insurance coverage.
Through a series of strategic structural changes to its health system, catalyzed through international assistance,
Rwanda has demonstrated a commitment towards improving patient and population health indicators. In
particular, the rapid scale up of antiretroviral therapy (ART) has become a great success story for Rwanda. The
country achieved universal coverage of ART at a CD4 cell count of 200 cells/mm3 in 2007 and increased the
threshold for initiation of ART to ≤350 cells/mm3 in 2008. Further, 2013 guidelines raised the threshold for initiation
to ≤500 cells/mm3 and suggest immediate therapy for key affected populations. In 2015, guidelines recommend
offering immediate treatment to all patients. By reviewing the history of HIV and the scale-up of treatment delivery
in Rwanda since the genocide, this paper highlights some of the key innovations of the Government of Rwanda
and demonstrates the ways in which the national response to the HIV epidemic has catalyzed the implementation
of interventions that have helped strengthen the overall health system.
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Background
Rwanda is a landlocked country in the Great Lakes re-
gion of East Africa, bordered by Uganda, Tanzania,
Burundi, and the Democratic Republic of the Congo. It
has a predominantly dense, but mainly rural population
and the average age of Rwandans is 22.7 years [1]. The
population of Rwanda has grown at a rate of 2.6 % every
year from 2002 to 2012 and is expected to reach 13.3
million by 2022.
On July 1, 1962, Rwanda was granted full political in-
dependence from Belgium, following colonial rule since
1923. In the years following independence, the Govern-
ment of Rwanda, dominated by Hutu extremists, began
systematically oppressing the Tutsi minority population.
In April of 1994, in a terror that lasted 100 days, Rwanda’s
infrastructure and human resources were catastrophically
damaged by a genocide that claimed the lives of more than
1,000,000 Tutsis and moderate Hutus. When the genocide
ended, a new government began the difficult process of
returning peace, security, and stability to the country.
In 2005, in combination with many efforts to reclaim
Rwanda’s prosperity, the Government of Rwanda began
reforming operations, including redistricting internal
geopolitical boundaries and a decentralization of govern-
ance systems, such as the health sector. These reforms
now define the five provinces, with 30 districts per prov-
ince. These are further subdivided into sectors, each con-
taining 14,953 umudugus (villages) of approximately 50 to
100 households. This intentional, structural organization
of Rwanda has helped the country achieve greater
decentralization and localization of health care in a way
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that has substantially improved its population health.
Rwanda has among the best population health indicators
in the region and the country has almost met each of the
health-related Millennium Development Goals [2, 3].
More than 97 % of Rwandan infants are vaccinated against
ten different diseases and 69 % of births are attended to by
trained clinicians at health facilities [2, 3]. Premature mor-
tality rates have fallen precipitously in recent years, and
life expectancy has almost doubled since the end of the
genocide in 1994 [4].
The strengthening of the health sector in the 20 years
since the end of the genocide is tightly linked to Rwanda’s
response to the HIV epidemic. Through a series of stra-
tegic decisions, the formation of strong partnerships and
global mobilization of resources, Rwanda has made re-
markable progress at scaling up access to antiretroviral
therapy (ART) and improving the delivery of care and sup-
port to an estimated 204,899 people living with HIV in the
country [5]. Prior to 2002, there were less than 100 people
on ART. Today, more than 150,000 patients are on treat-
ment (Fig. 1). This scale-up occurred by incrementally
raising the CD4 threshold for access to treatment. Rwanda
first achieved universal coverage of ART at a CD4 cell
count threshold of 200 cells/mm3 in 2007, increased the
threshold to ≤350 cells/mm3 in 2008, and 2013 guidelines
raised it to ≤500 cells/mm3, with exceptions for immediate
therapy for key populations. In 2015, guidelines have rec-
ommended offering immediate treatment to all patients
regardless of CD4 eligibility. It is through this scale-up
that we describe some of the key innovations in the health
system in the previous two decades and demonstrate how
these innovations have helped strengthen the overall
population health of the country.
HIV and the genocide against Tutsis in Rwanda, 1994
HIV was first reported in Rwanda in 1983 by a team of
Belgian scientists. In 1986, the nation conducted its first
population-based sero-prevalence survey that reported an
urban prevalence of 18 % and a rural prevalence of 1 %
[6]. For nearly a decade after, there was little awareness of
HIV/AIDS, and most physicians were unable to recognize,
diagnose, or treat the condition. People living with HIV
were kept in isolation wards with poor sanitary conditions
and without safety precautions to prevent transmission
between patients and hospital staff. There was little to no
access to HIV treatment in Rwanda prior to 1994.
Fig. 1 Decline in new HIV infections (blue line) and increasing coverage of antiretroviral therapy (ART) in Rwanda, 2004–2015. Source: Institute of
HIV/AIDS Disease Prevention & Control, Rwanda Biomedical Centre; reproduced with permission
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The 1994 genocide profoundly set back all of Rwanda’s
development efforts. In the wake of the 100-days of killing,
two million were left homeless and the health system had
collapsed [7]. Rape, as a weapon of war, was used against
more than 250,000 women and helped fuel a sharp in-
crease in HIV infections after the genocide [8]. Large
population migrations in and out of Rwanda in the years
that followed the genocide made it difficult for authorities
to detect and control the spread of new infections [9]. The
genocide led to a ruin of physical health infrastructure
(hospitals, clinics, public health labs, etc.) and generated a
massive exodus of skilled medical personnel. By the end of
the genocide, nearly 80 % of physicians had been killed or
had fled the country [10]. Fewer than ten pediatricians
were practicing in all of Rwanda in the year that followed.
It was an event that had a profound effect on the identity
of the nation and its response to HIV since 1994 has been
a demonstration of the resiliency of humanity.
Approaching the HIV epidemic after the genocide,
1996–2002
In 1995, the National Program for HIV/AIDS Control
(PNLS) was re-established with a renewed mission to
control the AIDS epidemic in Rwanda. The initial goal of
the PNLS was to educate Rwandans about how to prevent
HIV infection. The campaign first gained momentum
when President Kagame spontaneously attended a PNLS
conference, voicing his support for the battle against HIV/
AIDS and declaring it a top priority for his administration.
However, like many sub-Saharan African countries at the
time, limited government resources with limited foreign
assistance made the high cost of HIV treatment prohibi-
tively out of reach. In 1999, treatment costs were as high
as US$ 6,065 per patient per year, and antiretroviral prices
would account for 92 % of the total cost of care. Only 202
people living with HIV in Rwanda at this time were able
to afford the out-of-pocket expense of purchasing ART on
a global market [11].
By 1999, the Ministry of Health had begun expanding
HIV testing facilities and laboratory capacity to prepare for
expanding access to ART. In early 2000, the universal treat-
ment program began with a small government created fund
to offer free ART at the Kigali Teaching Hospital. Mean-
while, medical practitioners had begun intensive HIV clin-
ical and administrative training within and outside Rwanda.
Training also helped improve record keeping and reporting
practices. By the early 2000s, HIV program scale-up was
ready to take shape, but funding remained a limiting factor.
Funding, scale-up, decentralization, and the integration of
programs 2002–2007
In 2002, two major events catalyzed the scale-up of
Rwanda’s HIV program. First, the Ministry of Health
disseminated standardized, national protocols that gave
medical centers, district hospitals, and referral centers
authorization and instructions for providing care to
people living with HIV. Protocols were drafted based on
similar documents written by the United States Centers
for Disease Control and focused on training healthcare
providers to perform diagnoses and facilitate patient re-
tention through follow-up. Second, major sources of
funding, beginning in 2002, helped accelerate the expan-
sion of HIV services. Initial funding came from the
World Bank in the form of a US$ 30.5 million 3-year
award to scale-up access to testing, mitigate the social
impact of HIV, and purchase ART for those in need.
This was closely followed by the Global Fund to Fight
AIDS, Tuberculosis and Malaria, awarding Rwanda US$
34 million to further strengthen health facility capacity
for testing and treatment and to scale-up prevention of
mother-to-child transmission (PMTCT) services. The
same year, the US President’s Emergency Plan for AIDS
Relief (PEPFAR) was launched and granted Rwanda US$
39 million to support increased access to ART and
PMTCT programs.
The influx of funding in 2002, delivered by a multi-
tude of partnerships with NGOs and international do-
nors, occurred in the context of a weaker government
capacity. The proliferation of NGO involvement in
Rwanda often led to a duplication of services, stemming
from poor coordination between the government and
the many independent agencies providing care. Each
partner used different approaches and reporting chan-
nels and there was limited enforcement of the strategies
created under PNLS. Some implementing partners re-
ported directly to their donors without providing any
information to the Government of Rwanda. This se-
verely limited access to critical information such as data
on epidemiological trends to monitor and inform the
progress of the national response. This led to the devel-
opment of a technical coordination team in 2005 that
aimed to coordinate decision-making and draft new
guidelines and protocols for HIV service delivery in
Rwanda. The group was led by the PNLS and included
representatives from US government organizations
(CDC, PEPFAR, USAID) and UN partners (WHO,
UNICEF, UNAIDS), as well as faith-based organizations
and local NGOs. The team was charged with the formid-
able task of promoting the integration of funds and ser-
vices, expanding the geographical reach of programs,
increasing health worker performance, improving financial
accessibility and accountability, improving overall aware-
ness of HIV, and decreasing stigma and discrimination.
Over the next several years, the coordination of
HIV services in Rwanda was scaled-up by focusing on
the decentralization of care. This is depicted in Fig. 2,
which shows the number and location of HIV services
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in Rwanda in 2004 on the left and in 2013 on the
right. As of 2013, more than 465 health facilities now
provide HIV services, including delivery of ART [5].
This was achieved by making training investments in
health facilities, strategic decisions on the supply
chain of ART across the country, and continuously
reviewing HIV protocols to keep up to date with glo-
bal treatment guidelines. Patient and pharmacy files
were standardized and reporting for routine monitor-
ing and evaluation was made easier for local health
facilities. This included the development of a stan-
dardized web-based electronic reporting system called
TRACnet, launched in 2005 and which replaced the
paper-based facility-level reporting system with one-
way mobile phone technology that sent a standardized
set of monthly health indicators to a centralized data-
base in Kigali. Today, the TRACnet database has con-
tinued to permit real-time monitoring and evaluation
of the national HIV care program, providing empirical
evidence for the cumulative number of people on
ART and the rate of new diagnoses (Fig. 1).
Supporting health system innovations
There were a number of other secondary health system
innovations that also helped strengthen Rwanda’s HIV
response. Some international donors, particularly the
Global Fund, were more open to funding more non-
disease specific interventions that indirectly helped
foster the scale-up of the HIV program, and improve
overall population health. Two notable health system in-
terventions that helped achieve this were the Multelles
de santé, a community-based mutual insurance scheme,
and the implementation of a performance-based health
financing (PBF) scheme [12].
The high financial burden of user fees led to an over-
all decline in per-capita visits to health care facilities be-
tween 1997 and 1999 [13]. The inaccessibility of health
services to the poor led implementers in Rwanda to test
a pre-payment, community-based mutual insurance
scheme in three districts of Rwanda, namely the
Mutuelles. The Government of Rwanda began imple-
menting the Mutuelles in 1999 to provide affordable
basic services, especially child and maternal care, to the
Fig. 2 The decentralization of HIV services depicted by the number and location of services in Rwanda in 2004 (left) and in 2013 (right).
Source: Institute of HIV/AIDS Disease Prevention & Control, Rwanda Biomedical Centre; reproduced with permission
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uninsured population. Over the next 7 years, the pro-
gram was brought to scale and solidified into law in
2008. Approximately half of funding for the Mutuelles
comes from annual member premiums. The remaining
half is obtained through transfers from other insurance
funds, charitable organizations, NGOs, development
partners, and the Government of Rwanda. In particular,
the Global Fund to Fight AIDS, Tuberculosis and
Malaria funded the annual premium costs for the poor-
est 16 % of the population [14]. An impact evaluation of
the Mutuelles has shown an increase in the utilization
of healthcare and a decrease in catastrophic health
spending among its members [15]. The Mutuelles pro-
gram has successfully demonstrated that eliminating fi-
nancial barriers to healthcare increases health service
utilization and improves population-level health out-
comes for all, including people living with HIV [14, 15].
The second major health system innovation was the
implementation of PBF in 2001. The Government of
Rwanda partnered with two NGOs and the School of
Public Health at the National University of Rwanda to
experiment with the implementation of PBF. The PBF
program provided payments to health workers to
incentivize high-quality care and, in 2006, the program
was scaled-up across the country [16]. Incentives were dis-
tributed to health facilities based on the facility’s quality
performance measures. The HIV program particularly
benefited from the implementation of PBF, since payments
were given for several key HIV care indicators, including
the number of new adults and infants on ART, the num-
ber of HIV-positive pregnant mothers put on ART during
pregnancy, and the number of HIV patients who receive a
CD4 test in accordance with national guidelines. The pro-
gram has been shown to have an effect on several health
outcomes and it continues to be empirically evaluated and
discussed in the literature [16, 17].
Financial sustainability and human resource challenges,
2008 to present
In 2011, existing HIV coordinating mechanisms were
dissolved and restructured into the Rwanda Biomedical
Center to facilitate better integration with other disease-
specific programs and create operational efficiencies that
would generate more value in the face of declining
resources. Rwanda was among the first countries to
dissolve its national AIDS control commission in
favor of a more integrated approach. By 2012, 97 %
of all health facilities offered voluntary counseling and
testing services, 97 % of all health facilities offered
PMTCT services, and 89 % of all health facilities offered
ART [18]. This has translated into impressive health
outcomes for people living with HIV in Rwanda,
including increased life expectancy [19] and high rates
of retention in care [20, 21].
Yet, despite the many successes in Rwanda’s response to
HIV, these health system gains remain fragile. As external
donor funding for HIV programs has continued to decline
at a rapid rate, the need for new resources to support pro-
gramming has become increasingly crucial. By 2014, the
annual cost of sustaining Rwanda’s HIV programs had
grown to nearly US$ 200 million. This comprehensive
budget, that supports HIV prevention, treatment, and
control programming, was 80 % funded by external sup-
porters. An overall decline in foreign assistance means the
government must look to new ways to innovate its health
system in an effort to improve financial sustainability
while not compromising gains made in health outcomes.
This challenge is depicted in Fig. 3, which shows the
Fig. 3 Funding changes since 2010 and predictions for future funding challenges for the HIV program in Rwanda. Source: Institute of HIV/AIDS
Disease Prevention & Control, Rwanda Biomedical Centre; reproduced with permission
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estimated funding gap for supporting the HIV program in
Rwanda in future years.
In an effort to address the substantial burden of
labor costs in the HIV program, the Rwanda devel-
oped new policies for the implementation of human
resource task shifting in 2010. The program to train
more than 500 nurses to deliver HIV care, including
prescribing ART, has achieved high levels of retention
and improved patient health outcomes [22]. The task
shifting momentum also catalyzed the training of
more than 45,000 community healthcare workers in
Rwanda. This program has been successfully demon-
strated to further improve patient retention in care,
treatment, and support and minimize loss to follow-up
[21]. Since 2012, these programs have been strength-
ened by the Human Resources for Health Program,
focusing on knowledge transfer, sustained collabor-
ation, and the establishment of a new medical residency,
nursing specialty, health management, and oral health
programs within the Rwandan education system [23]. As
Rwanda works to become more financially sustainable
in the delivery of HIV program services, strengthening
human resources and maximizing efficiencies will be a
key component of its strategy. Task shifting in other
clinical areas and integrating these clinical areas
within the existing training environment in the field
of HIV can help achieve greater overall health system
development.
Conclusions and lessons learned
Rwanda has made remarkable development progress in
the 20 years since the end of the genocide against the
Tutsis. A strong commitment to an integrated and
evidence-based response to the HIV epidemic has fos-
tered substantial improvements in health outcomes for
all Rwandans. Many countries in sub-Saharan Africa are
also looking to innovative ways address their own HIV
epidemics. The evolution of HIV program scale-up in
Rwanda should teach us that strong leadership and the
investment of resources in programs that strengthen
the health system as a whole are some of the architec-
tural features of health development in Rwanda that
are laudable. The small country with a population that
also speaks the same language has fostered the
decentralization of services during their scale-up, which
has also contributed to Rwanda’s overall success. Some
aspects of the health systems innovations described in
this paper are transferable to other countries; others are
not. However, common to all sub-Saharan African
countries, is a crucial need to find new efficiencies
through better integration of delivery systems, revenue
and funding streams, and local, regional, and global co-
operation to continue improving the delivery of HIV
program services.
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